Outcomes for Patients with Locally Advanced Pancreatic Cancer
Author Information
Author(s): Larsson Patrik, Swartling Oskar, Cheraghi Diana, Khawaja Ajnon, Søreide Kjetil, Sparrelid Ernesto, Ghorbani Poya
Primary Institution: Karolinska Institute
Hypothesis
What are the survival outcomes for all patients with locally advanced pancreatic cancer (LAPC) in the Stockholm region?
Conclusion
Patients with LAPC who received neoadjuvant chemotherapy and underwent resection had better survival than those who did not undergo resection.
Supporting Evidence
- Survival outcomes were analyzed for all patients with LAPC in the Stockholm region.
- Neoadjuvant chemotherapy followed by resection improved survival rates.
- The study utilized a population-based health care system to avoid referral bias.
Takeaway
This study looked at patients with a type of pancreatic cancer and found that those who had surgery after chemotherapy lived longer than those who didn't have surgery.
Methodology
The study analyzed survival outcomes for all patients with LAPC in a population-based health care system without referral bias.
Potential Biases
There may be risks of bias due to the unselected cohort and reliance on intention-to-treat analysis.
Limitations
The study may not account for all variables affecting survival outcomes due to its observational nature.
Participant Demographics
Patients were from the Stockholm region and included all individuals diagnosed with LAPC.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website